XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “C ...

Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease ProgramsCALGARY, Alberta, April 28, 2025 (GLOBE ...

JAK inhibitors, such as ruxolitinib cream and abrocitinib, present promising alternatives to existing therapies for managing moderate to severe atopic dermatitis, offering effective treatment options.

We have previously shown that inhibition of polyamine oxidase (PAO) using MDL 72527 significantly reduced retinal neurodegeneration and cell death signaling pathways in hyperoxia-mediated retinopathy.